Opdivo (nivolumab) Letter of Medical Necessity
Opdivo (nivolumab) PA decisions hinge on tumor-specific biomarker results, line of therapy, and the specific regimen requested. Precise documentation prevents most denials.
FDA-Approved Indications
- ● melanoma
- ● NSCLC
- ● renal cell carcinoma
- ● classical Hodgkin lymphoma
- ● urothelial
- ● colorectal MSI-H
- ● hepatocellular
- ● esophageal/gastric and others
Why Opdivo Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Biomarker testing missing
- 2. Line of therapy not specified
- 3. Combination not on label
What to Include in a Opdivo Letter of Medical Necessity
Document tumor type/stage/histology, biomarker results, prior therapies, ECOG status, the regimen (mono vs combo with ipilimumab/chemo), and the supporting NCCN evidence category.
Key clinical evidence to cite:
- ✓ CheckMate trial series across tumor types
- ✓ CheckMate-067 for melanoma
- ✓ CheckMate-9LA for NSCLC
Relevant guidelines:
- 📖 NCCN guidelines per tumor type
- 📖 ASCO guidelines
Opdivo Prior Authorization Criteria
Standard criteria across major US payers for Opdivo. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Opdivo
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Opdivo Prior Authorization FAQ
Why was my Opdivo prior authorization denied?
The most common denial reasons for Opdivo are: Biomarker testing missing; Line of therapy not specified; Combination not on label.
What should a Opdivo Letter of Medical Necessity include?
Document tumor type/stage/histology, biomarker results, prior therapies, ECOG status, the regimen (mono vs combo with ipilimumab/chemo), and the supporting NCCN evidence category.
Which payers cover Opdivo?
Opdivo is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.